…
Ayurcann Holdings Corp. provides post-harvest outsourcing solutions to licensed cannabis producers in Canada. The company offers extraction, processing, and co-manufacturing of pharma grade cannabis to produce various derivative cannabis products in the medical and recreational markets. It also manufactures and distributes cannabis products. The company sells product under the Fuego, H&S, and XPLOR brand names. Ayurcann Holdings Corp. is headquartered in Pickering, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Publicly available information on Ayurcann Holdings Corp (OTCQB: AYURF) is limited; the company is associated with the cannabis/hemp sector. Potential long-term drivers include expanding legal cannabis markets and broader medical and consumer adoption, which could provide small-cap exposure to industry growth for investors willing to accept limited disclosure.
Primary risks are scarce public disclosure and OTC liquidity constraints, combined with regulatory uncertainty and strong competition in the cannabis sector.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Income before tax | -3.49M | -3.97M | -5.31M | -1.73M | 0.06M |
| Net income | -3.49M | -3.97M | -5.31M | -3.09M | -0.28M |
| Selling general administrative | 12.02M | 10.53M | 8.22M | 5.51M | 2.46M |
| Gross profit | 10.16M | 8.47M | 3.68M | 3.92M | 4.63M |
| Reconciled depreciation | 0.98M | 1.24M | 0.78M | 0.32M | 0.28M |
| Ebit | - | - | - | -3.33M | 2.16M |
| Ebitda | - | - | - | -1.32M | 0.65M |
| Operating income | -2.46M | -2.79M | -4.99M | -1.60M | 2.16M |
| Interest expense | 0.66M | 0.72M | 0.03M | 0.09M | 0.32M |
| Tax provision | - | - | 0.00M | -0.34M | 0.34M |
| Net interest income | -0.66M | -0.72M | -0.03M | -0.09M | -0.32M |
| Income tax expense | - | - | - | -0.34M | 0.34M |
| Total revenue | 31.11M | 25.16M | 12.49M | 11.08M | 7.63M |
| Total operating expenses | 33.57M | 27.95M | 17.48M | 12.68M | 5.47M |
| Cost of revenue | 20.95M | 16.69M | 8.81M | 7.17M | 3.01M |
| Total other income expense net | -0.36M | -0.46M | -0.29M | -0.04M | -1.79M |
| Net income from continuing ops | -3.49M | -3.97M | -5.31M | -1.39M | -0.28M |
| Net income applicable to common shares | - | - | - | -3.09M | -0.28M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Total assets | 12.68M | 14.85M | 12.73M | 7.28M | 6.68M |
| Intangible assets | 1.20M | 1.75M | 2.30M | - | - |
| Total liab | 15.63M | 14.32M | 10.04M | 2.39M | 1.93M |
| Total stockholder equity | -2.95M | 0.53M | 2.69M | 4.89M | 4.75M |
| Other current liab | - | - | - | - | 0.34M |
| Common stock | - | - | - | 8.05M | 5.79M |
| Capital stock | 12.95M | 12.95M | 11.16M | 8.05M | 5.79M |
| Retained earnings | -17.86M | -14.38M | -10.41M | -5.10M | -2.02M |
| Cash | 1.99M | 0.39M | 0.97M | 1.35M | 0.73M |
| Total current liabilities | 15.09M | 13.60M | 9.98M | 2.17M | 1.57M |
| Short long term debt | 0.04M | 0.04M | - | - | - |
| Other stockholder equity | - | - | - | 0.94M | 0.13M |
| Property plant equipment | - | - | - | 1.19M | 1.25M |
| Total current assets | 10.21M | 11.50M | 9.27M | 6.09M | 5.43M |
| Net tangible assets | - | - | - | 4.89M | 4.75M |
| Net receivables | 3.96M | 5.24M | 4.84M | 1.54M | 2.08M |
| Long term debt | 0.09M | 0.13M | - | 0.04M | 0.04M |
| Inventory | 3.72M | 5.36M | 3.28M | 2.95M | 2.32M |
| Accounts payable | 3.33M | 4.17M | 2.07M | 0.91M | 1.00M |
| Non current assets total | 2.46M | 3.36M | 3.46M | 1.19M | 1.25M |
| Capital lease obligations | 0.59M | 0.73M | 0.18M | 0.32M | 0.44M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Investments | -0.09M | -0.44M | -0.30M | -0.26M | 0.36M |
| Change to liabilities | - | - | - | 0.91M | 0.95M |
| Total cashflows from investing activities | - | - | - | -0.26M | 0.36M |
| Net borrowings | -0.68M | -0.05M | - | -0.18M | -0.27M |
| Total cash from financing activities | -0.68M | -0.05M | 0.19M | 0.94M | 0.54M |
| Change to operating activities | - | - | - | -0.02M | -0.32M |
| Net income | -3.49M | -3.97M | -5.31M | -3.09M | -0.28M |
| Change in cash | 1.60M | -0.58M | -0.38M | 0.63M | 0.70M |
| Begin period cash flow | 0.39M | 0.97M | 1.35M | 0.73M | 0.02M |
| End period cash flow | 1.99M | 0.39M | 0.97M | 1.35M | 0.73M |
| Total cash from operating activities | 2.37M | -0.10M | -0.27M | -0.05M | -0.20M |
| Issuance of capital stock | - | - | 0.00M | 1.39M | 0.77M |
| Depreciation | 0.98M | 1.24M | 0.78M | 0.32M | 0.28M |
| Change to inventory | 1.64M | -2.09M | -0.33M | -0.63M | -2.04M |
| Change to account receivables | 1.27M | -0.39M | -3.79M | 0.66M | -1.71M |
| Sale purchase of stock | - | 0.00M | -0.02M | -0.26M | - |
| Other cashflows from financing activities | - | - | - | - | 0.04M |
| Change to netincome | - | - | - | 2.15M | 2.30M |
| Capital expenditures | 0.09M | 0.44M | 0.30M | 0.26M | 0.51M |
| Change in working capital | 4.77M | 2.16M | 2.34M | 0.58M | -2.78M |
| Stock based compensation | 0.00M | 0.41M | 1.53M | 2.11M | 0.13M |
| Other non cash items | 0.11M | 0.07M | 0.03M | 0.03M | 2.44M |
| Free cash flow | 2.28M | -0.53M | -0.57M | -0.31M | -0.71M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AYURF Ayurcann Holdings Corp |
- -% |
0.00 | - | - | 0.01 | 2.70 | 0.06 | -1.05 |
| MKKGY Merck KGaA ADR |
-0.68 2.09% |
31.83 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
163.45 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.38 1.77% |
21.79 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.05 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Ayurcann Holdings Corp. provides post-harvest outsourcing solutions to licensed cannabis producers in Canada. The company offers extraction, processing, and co-manufacturing of pharma grade cannabis to produce various derivative cannabis products in the medical and recreational markets. It also manufactures and distributes cannabis products. The company sells product under the Fuego, H&S, and XPLOR brand names. Ayurcann Holdings Corp. is headquartered in Pickering, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Igal Sudman | Co-Founder, Corp. Sec., CEO & Chairman | NA |
| Mr. Buzaker Roman | Co-Founder, Pres, CFO, COO & Director | NA |
| Mr. Raj Virk | Head of Quality & Compliance | NA |
| Mr. Igal Sudman | Co-Founder, Corporate Secretary, CEO & Chairman | NA |
| Mr. Buzaker Roman | Co-Founder, President, COO & Director | NA |
| Mr. Yisroel Zuchter | Chief Financial Officer | NA |
| Mr. Roman Buzaker | Co-Founder, President, COO & Director | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.